Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
StemSight Oy maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are currently 2 pending office actions for this entity. This indicates that the company is pursuing multiple patent grants within its primary field of innovation. The volume of 2 pending actions suggests an active prosecution phase.
The 2 pending office actions are assigned to 1 distinct examiner. This examiner operates within 1 distinct art unit. This concentration of work means that all current prosecution activity for the company is being reviewed by the same individual. Such a setup can lead to consistency in the feedback received from the patent office, as the same 1 examiner evaluates the technical merits of the pending matters.
REGLAS, GILLIAN CHELSEA is identified as the busiest examiner for StemSight Oy, with 2 busiest examiner pending office actions. This count of 2 matches the total number of pending office actions for the portfolio. Because 1 distinct examiner is responsible for all 2 pending actions, the applicant's entire current prosecution strategy is focused on the interactions with REGLAS, GILLIAN CHELSEA within that 1 art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REGLAS, GILLIAN CHELSEA | 2 | 32.3% | +37.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044061 | METHOD FOR DIFFERENTIATING CORNEAL ENDOTHELIAL CELL-LIKE CELLS FROM PLURIPOTENT STEM CELLS | REGLAS, GILLIAN CHELSEA | 4d overdue |
| 17600457 | METHOD FOR OBTAINING OR MAINTAINING ABCG2-POSITIVE CORNEAL LIMBAL STEM CELLS | REGLAS, GILLIAN CHELSEA | — |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18044061 | METHOD FOR DIFFERENTIATING CORNEAL ENDOTHELIAL CELL-LIKE CELLS FROM PLURIPOTENT STEM CELLS | REGLAS, GILLIAN CHELSEA | 1632 | §103 | Non-Final OA | 4d overdue | Pending | Mar 03, 2023 |
| 17600457 | METHOD FOR OBTAINING OR MAINTAINING ABCG2-POSITIVE CORNEAL LIMBAL STEM CELLS | REGLAS, GILLIAN CHELSEA | 1632 | §103 | Final Rejection | — | Pending | Sep 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStemSight Oy has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gillian Chelsea Reglas has the most, with 2 of StemSight Oy's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
